The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
Open accessAbstract
Purpose: Most patients with advanced ovarian cancer develop recurrent disease. For those patients who recur at least 6 months after initial therapy, paclitaxel platinum has shown a modest survival advantage over platinum without paclitaxel; however, many patients develop clinically relevant neurotoxicity, frequently resulting in treatment discontinuation. Thus, an alternative regimen without significant neurotoxicity was evaluated by comparing gemcitabine plus carboplatin with single-agent carboplatin in platinum-sensitive recurrent ovarian cancer patients. Methods: Patients with platinum-sensitive recurrent ovarian cancer were randomly assigned to receive either gemcitabine plus carboplatin or carboplatin alone, every 21 days. The primary objective was to compare progression-free survival (PFS). Results: Three hundred fifty-six patients (178 gemcitabine plus carboplatin; 178 carboplatin) were randomly assigned. Patients received a median of six cycles in both arms. With a median follow-up of 17 months, median PFS was 8.6 months (95% CI, 7.9 to 9.7 months) for gemcitabine plus carboplatin and 5.8 months (95% CI, 5.2 to 7.1 months) for carboplatin. The hazard ration (HR) for PFS was 0.72 (95% CI, 0.58 to 0.90; P = .0031). Response rate was 47.2% (95% CI, 39.9% to 54.5%) for gemcitabine plus carboplatin and 30.9% (95% CI, 24.1% to 37.7%) for carboplatin (P = .0016). The HR for overall survival was 0.96 (95% CI, 0.75 to1.23; P = .7349). While myelosuppression was significantly more common in the combination, sequelae such as febrile neutropenia or infections were uncommon. No statistically significant differences in quality of life scores between arms were noted. Conclusion: Gemcitabine plus carboplatin significantly improves PFS and response rate without worsening quality of life for patients with platinum-sensitive recurrent ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Ozols, R. F., Bundy, B. N., Greer, B. E., Fowler, J. M., Clarke-Pearson, D., Burger, R. A., Mannel, R. S., DeGeest, K., Hartenbach, E. M., & Baergen, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.153 · Cited by 2,032
Carboplatin dosage: prospective evaluation of a simple formula based on renal function.
Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., & Wiltshaw, E. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.11.1748 · Cited by 1,866
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
Self-citationSecond-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Trotti, A., Byhardt, R., Stetz, J., Gwede, C., Corn, B., Fu, K., Gunderson, L., McCormick, B., Morris∫, M., Rich, T., et al. (2000) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00559-3 · Cited by 804
Tables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 718
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
Green, S., & Weiss, G. R. (1992) · Investigational New Drugs · doi:10.1007/bf00944177 · Cited by 610
Cited by
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Self-citationOlaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Self-citationJayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz062 · Cited by 1,197
Self-citationLedermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N., & Sessa, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt333 · Cited by 1,104
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945
Treatment of epithelial ovarian cancer
Kuroki, L., & Guntupalli, S. R. (2020) · BMJ · doi:10.1136/bmj.m3773 · Cited by 873
Recent progress in the diagnosis and treatment of ovarian cancer
Jelovac, D., & Armstrong, D. K. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20113 · Cited by 765
Bookman, M. A., Brady, M. F., McGuire, W. P., Harper, P. G., Alberts, D. S., Friedlander, M., Colombo, N., Fowler, J. M., Argenta, P. A., De Geest, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.1684 · Cited by 705
Hennessy, B. T., Coleman, R. L., & Markman, M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61338-6 · Cited by 640
Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B.-G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30279-6 · Cited by 609
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585
de Sousa Cavalcante, L., & Monteiro, G. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.041 · Cited by 576
Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 575
Self-citationPlatinum neurotoxicity pharmacogenetics
McWhinney, S. R., Goldberg, R. M., & McLeod, H. L. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0840 · Cited by 574
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
Self-citationAdvances in targeting the folate receptor in the treatment/imaging of cancers
Fernández, M., Javaid, F., & Chudasama, V. (2018) · Chemical Science · doi:10.1039/c7sc04004k · Cited by 539
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Ovarian cancer: Current status and strategies for improving therapeutic outcomes
Chandra, A., Pius, C., Nabeel, M., Nair, M., Vishwanatha, J. K., Ahmad, S., & Basha, R. (2019) · Cancer Medicine · doi:10.1002/cam4.2560 · Cited by 449
González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R. E., Pothuri, B., Ray-Coquard, I., Tan, D. S. P., Bellet, E., Oaknin, A., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.07.011 · Cited by 449
Colombo, N., Sessa, C., Bois, A. D., Ledermann, J., McCluggage, W., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000308 · Cited by 407
Self-citationTrabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer
Monk, B. J., Herzog, T. J., Kaye, S. B., Krasner, C. N., Vermorken, J. B., Muggia, F. M., Pujade-Lauraine, E., Lisyanskaya, A. S., Makhson, A. N., Rolski, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4037 · Cited by 395
Self-citationCytoreductive surgery for recurrent ovarian cancer: A meta-analysis
Bristow, R. E., Puri, I., & Chi, D. S. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.08.033 · Cited by 374
Treatment of recurrent ovarian cancer
Pignata, S., C Cecere, S., Du Bois, A., Harter, P., & Heitz, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx441 · Cited by 338
Self-citationTen-Year Relative Survival for Epithelial Ovarian Cancer
Baldwin, L. A., Huang, B., Miller, R. W., Tucker, T., Goodrich, S. T., Podzielinski, I., DeSimone, C. P., Ueland, F. R., van Nagell, J. R., & Seamon, L. G. (2012) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e318264f794 · Cited by 336
Hanker, L. C., Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E., Ray-Coquard, I., Sehouli, J., Harter, P., & du Bois, A. (2012) · Annals of Oncology · doi:10.1093/annonc/mds203 · Cited by 329
Self-citationAghajanian, C., Goff, B., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.004 · Cited by 320
Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
Pol, J., Vacchelli, E., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Sautès-Fridman, C., Fucikova, J., Galon, J., Spisek, R., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008866 · Cited by 305
Caruso, G., Weroha, S. J., & Cliby, W. (2025) · JAMA · doi:10.1001/jama.2025.9495 · Cited by 304
Monk, B. J., Poveda, A., Vergote, I., Raspagliesi, F., Fujiwara, K., Bae, D.-S., Oaknin, A., Ray-Coquard, I., Provencher, D. M., Karlan, B. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70244-x · Cited by 304
Self-citationFojo, T., Mailankody, S., & Lo, A. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 303
Domchek, S. M., Aghajanian, C., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.020 · Cited by 297
Ferrandina, G., Ludovisi, M., Lorusso, D., Pignata, S., Breda, E., Savarese, A., Del Medico, P., Scaltriti, L., Katsaros, D., Priolo, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6606 · Cited by 289
Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing Therapy
Romero, I., & Bast, R. C. (2012) · Endocrinology · doi:10.1210/en.2011-2123 · Cited by 286
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential
Luvero, D., Milani, A., & Ledermann, J. A. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014544121 · Cited by 260
Promising molecular mechanisms responsible for gemcitabine resistance in cancer
Jia, Y., & Xie, J. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.07.003 · Cited by 170
Moore, K. N., O'Malley, D. M., Vergote, I., Martin, L. P., Gonzalez-Martin, A., Malek, K., & Birrer, M. J. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.017 · Cited by 82
Self-citationMahner, S., Meier, W., du Bois, A., Brown, C., Lorusso, D., Dell’Anna, T., Cretin, J., Havsteen, H., Bessette, P., Zeimet, A. G., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2014.11.017 · Cited by 70
Self-citationGladieff, L., Ferrero, A., De Rauglaudre, G., Brown, C., Vasey, P., Reinthaller, A., Pujade-Lauraine, E., Reed, N., Lorusso, D., Siena, S., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr441 · Cited by 69
Wang, Y., Chiou, Y.-S., Chong, Q.-Y., Zhang, M., Rangappa, K. S., Ma, L., Zhu, T., Kumar, A. P., Huang, R. Y.-J., Pandey, V., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00064 · Cited by 20
Meteran, H., Knudsen, A. Ø., Jørgensen, T. L., Nielsen, D., & Herrstedt, J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13030897 · Cited by 12
Penson, R. T., Ambrosio, A. J., Whalen, C. A., Krasner, C. N., Konstantinopoulos, P. A., Bradley, C., Matulonis, U. A., & Birrer, M. J. (2023) · The Oncologist · doi:10.1093/oncolo/oyac275 · Cited by 12
Metadata
- Authors
- Pfisterer, J., Plante, M., Vergote, I., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Lück, H.-J., Rochon, J., Zimmermann, A. H., & Eisenhauer, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-10-10
- Volume
- 24
- Issue
- 29
- Pages
- 4699-4707
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2104998982
- Cited by
- 754
- References
- 19
- FWCI
- 42.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.